100 years of Mycobacterium bovis bacille Calmette-Guérin
| Autor: | Peter Aaby, Stefan H. E. Kaufmann, Peter R. Donald, Marcel A. Behr, Mihai G. Netea, Anna M. Mandalakas, Christoph Lange |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Vaccines
Attenuated/immunology Mycobacterium bovis/immunology Tuberculosis lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] Disease Vaccines Attenuated History 21st Century Immunity medicine Animals Humans Tuberculosis Bovine/epidemiology Mycobacterium bovis Bladder cancer Attenuated vaccine biology business.industry History 19th Century History 20th Century biology.organism_classification medicine.disease BCG Vaccine/adverse effects Infectious Diseases Immunology BCG Vaccine Meningeal Tuberculosis Cattle Tuberculosis vaccines business Tuberculosis Bovine |
| Zdroj: | Lancet Infectious Diseases, 22, e2-e12 Lange, C, Aaby, P, Behr, M A, Donald, P R, Kaufmann, S H E, Netea, M G & Mandalakas, A M 2022, ' 100 years of Mycobacterium bovis bacille Calmette-Guérin ', The Lancet Infectious Diseases, vol. 22, no. 1, pp. e2-e12 . https://doi.org/10.1016/S1473-3099(21)00403-5 Lancet Infectious Diseases, 22, 1, pp. e2-e12 |
| ISSN: | 1473-3099 |
| DOI: | 10.1016/S1473-3099(21)00403-5 |
| Popis: | Item does not contain fulltext Mycobacterium bovis bacille Calmette-Guérin (BCG), an experimental vaccine designed to protect cattle from bovine tuberculosis, was administered for the first time to a newborn baby in Paris in 1921. Over the past century, BCG has saved tens of millions of lives and has been given to more humans than any other vaccine. It remains the sole tuberculosis vaccine licensed for use in humans. BCG provides long-lasting strong protection against miliary and meningeal tuberculosis in children, but it is less effective for the prevention of pulmonary tuberculosis, especially in adults. Evidence mainly from the past two decades suggests that BCG has non-specific benefits against non-tuberculous infections in newborn babies and in older adults, and offers immunotherapeutic benefit in certain malignancies such as non-muscle invasive bladder cancer. However, as a live attenuated vaccine, BCG can cause localised or disseminated infections in immunocompromised hosts, which can also occur following intravesical installation of BCG for the treatment of bladder cancer. The legacy of BCG includes fundamental discoveries about tuberculosis-specific and non-specific immunity and the demonstration that tuberculosis is a vaccine-preventable disease, providing a foundation for new vaccines to hasten tuberculosis elimination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|